Candice Horbacz
President Trump and his administration signaled throughout 2025 their intent to subject pharmaceutical products and ingredients to new tariffs, a move that, despite no new tariffs applying as of January 2026, continues to cast a shadow over the U.S. healthcare landscape. The potential imposition of these tariffs, estimated to increase costs for American households by billions, stems from an ongoing investigation into pharmaceutical imports and a broader "America First" trade agenda. Analysis suggests that a maximal approach for pharmaceutical tariffs could introduce an additional $23 billion in tariff costs, while even a more narrowly tailored approach would still add $19.7 billion, fundamentally altering the economic dynamics of drug procurement and development in the United States.
The Context: Trump’s Trade Policy and Section 232
The threat of pharmaceutical tariffs is not an isolated policy proposal but rather a continuation of the trade policies championed by the Trump administration during its previous term. Characterized by a willingness to employ tariffs as a strategic tool, the administration frequently imposed duties on goods from various countries, notably China, steel, and aluminum imports, under the banner of protecting American industries and national security. This approach often invoked Section 232 of the Trade Expansion Act of 1962, which grants the President authority to impose tariffs on imports deemed a threat to national security.
The specific focus on pharmaceuticals in 2025 and into 2026 stems from an ongoing Section 232 investigation into pharmaceutical imports. Proponents of such tariffs argue that a heavy reliance on foreign nations for essential medicines and their active pharmaceutical ingredients (APIs) poses a critical national security vulnerability, particularly in times of global health crises or geopolitical tensions. The COVID-19 pandemic, which exposed fragilities in global supply chains and highlighted the U.S.’s dependence on overseas manufacturing for vital medical supplies, further fueled these concerns. The administration’s rhetoric often emphasized the goal of reshoring manufacturing and bolstering domestic production capabilities to ensure a secure and resilient supply of medicines for the American populace.
A Chronology of Threats and Policy Signals
Throughout 2025, various statements from President Trump and his senior advisors indicated a strong inclination towards imposing tariffs on pharmaceutical imports. While specific dates for tariff implementation remained fluid, the intention was clear. Campaign rallies and policy white papers frequently highlighted the issue of high drug prices and the perceived unfairness of international trade practices in the pharmaceutical sector.
Early in 2025, discussions reportedly began within the administration regarding potential targets for new tariffs, with pharmaceuticals quickly emerging as a significant area of interest. The launch of a formal Section 232 investigation into pharmaceutical imports served as the primary legal and policy mechanism to explore and potentially justify these duties. This investigation sought to determine whether the volume and circumstances of pharmaceutical imports threatened to impair U.S. national security by undermining domestic manufacturing capacity or creating vulnerabilities in the healthcare system.
By late 2025, as the investigation progressed, the administration outlined several potential scenarios for tariff application, varying in scope and impact. While no new tariffs were officially enacted by January 2026, the legislative and executive groundwork had been laid, maintaining the imminent possibility of such measures. Industry stakeholders and economists closely monitored these developments, preparing for potential shifts in global supply chains and drug pricing structures.
The Immense Scale of Pharmaceutical Imports
The U.S. pharmaceutical market is heavily reliant on global supply chains for both finished drug products and the chemical ingredients necessary for their manufacture. In 2024, the United States imported substantial volumes of pharmaceutical goods. An estimated $225 billion worth of imports could potentially be impacted by the proposed tariffs, encompassing a wide array of medicines and pharmaceutical ingredients.
Breaking down these figures, the U.S. imported approximately $214 billion in finished medicines and an additional $63 billion in chemicals. Of these chemicals, an estimated $11.3 billion were specifically identified for pharmaceutical use. This combined total underscores the vast scope of the U.S.’s dependence on foreign sources for its drug supply.
A significant portion of these imports originates from the European Union, which accounted for 61 percent of imported medicines and 47 percent of pharmaceutical ingredients in 2024. Other major suppliers include countries in Asia and other regions. Notably, China, despite its prominent role in the global supply chain for many goods, accounted for less than 4 percent of overall U.S. pharmaceutical imports by value, though its role in specific critical APIs can be more significant. This geographic distribution highlights the complexity of disentangling the U.S. pharmaceutical supply chain from its global partners and the potential diplomatic ramifications of imposing tariffs.
Analyzing the Tariff Scenarios and Estimated Financial Burden
The analysis of potential pharmaceutical tariffs outlines three distinct scenarios, each applying a 25 percent tariff rate unless lower rates have been previously negotiated through trade agreements. These scenarios illustrate a range of potential financial impacts on the U.S. economy and healthcare system:
-
Maximal Application Scenario: This broadest approach targets all 815 pharmaceutical products and ingredients that were previously exempted from tariffs under Annex 3. Under this scenario, direct tariff payments to the U.S. government are estimated to reach $23 billion in 2026. This represents the highest potential cost, encompassing a vast array of prescription drugs, over-the-counter medications, and essential chemical components.
-
Targeted Subsection 30 Annex 3 Scenario: A slightly more focused approach would concentrate tariffs solely on goods imported under subsection 30 of Annex 3. This scenario would still result in substantial tariff payments, totaling an estimated $21.9 billion. While narrower than the maximal approach, it still covers a significant portion of pharmaceutical imports.
-
Narrowly Tailored (Excluding Generics) Scenario: This scenario represents the most restrictive application, targeting only branded drugs while exempting generic medications. Despite the exemption of generics, this approach is still projected to generate $19.7 billion in new tariff payments to the U.S. Treasury.
Across these three scenarios, the estimated increase in tariff costs ranges from $19.7 billion to $23 billion. It is important to note that these figures represent the direct payments made by importing firms to the U.S. government. However, the net revenue generated from these tariffs for the government would be slightly lower, estimated between $15.1 billion and $17.7 billion in 2026. This difference arises from a mechanical offsetting effect: tariff payments reduce business revenues, which in turn diminishes the tax base for federal income and payroll taxes. This means that while tariffs generate new revenue, they also lead to a reduction in other tax collections, resulting in a lower net fiscal gain for the government.
The Branded vs. Generic Drug Conundrum
A key consideration in the tariff debate is the potential exemption of generic drugs. While generic drugs constitute the vast majority of prescriptions filled in the United States—estimated at over 90 percent—their share of overall drug spending is significantly smaller. Branded drugs, despite being prescribed less frequently, account for nearly 90 percent of drug spending by value due to their higher prices and patent protection.
The analysis indicates that exempting generic drugs from new tariffs would have a relatively limited impact on the overall cost of the new tariffs. This is because the higher-value branded drugs would still be subject to the duties, capturing the lion’s share of the financial burden. While an exemption for generics might offer some relief to consumers purchasing these more affordable medications, the dominant impact would still fall on the more expensive branded pharmaceuticals, potentially leading to higher costs for patients and healthcare systems relying on these drugs.
Expected Reactions from Stakeholders
The prospect of pharmaceutical tariffs has elicited, and is expected to continue to elicit, strong reactions from a diverse range of stakeholders within the healthcare ecosystem:
- Pharmaceutical Industry: Groups such as the Pharmaceutical Research and Manufacturers of America (PhRMA), representing branded drug manufacturers, and associations for generic drug producers are expected to vociferously oppose such tariffs. Their arguments would likely center on increased production costs, which could stifle innovation, reduce investment in research and development (R&D), and ultimately hinder the discovery of new life-saving treatments. They would also warn of supply chain disruptions, potential drug shortages, and the inherent difficulty and cost of rapidly reshoring complex pharmaceutical manufacturing.
- Patient Advocacy Groups: Organizations advocating for patient access to affordable medications would likely express deep concern. They would argue that tariffs would inevitably lead to higher drug prices for consumers, exacerbating an already critical issue of drug affordability in the U.S. Their focus would be on the direct impact on patients’ wallets and the potential for reduced access to essential medicines.
- Economists and Trade Experts: Independent economists and trade policy experts generally view tariffs as a tax on domestic consumers and businesses. They would likely issue warnings about the inflationary pressures tariffs could create, the potential for retaliatory tariffs from trading partners, and the overall inefficiency and economic distortion caused by such trade barriers. Many would also highlight the regressive nature of tariffs, disproportionately affecting lower-income households.
- Government Officials (Supporting Tariffs): Officials within the administration advocating for the tariffs would likely reiterate national security concerns, emphasizing the need for domestic manufacturing resilience and reducing reliance on geopolitical rivals. They might argue that the tariffs would incentivize U.S. job creation and strengthen the domestic industrial base, potentially downplaying the immediate impact on consumer prices by suggesting that foreign producers or importing firms would absorb much of the cost.
- Healthcare Providers and Systems: Hospitals, clinics, and health insurance providers would likely raise concerns about the increased cost of procurement for a wide range of medications. Higher drug costs could translate into higher premiums, increased out-of-pocket expenses for patients, and budgetary strains for healthcare institutions already grappling with rising costs.
Broader Economic and Healthcare Implications
The imposition of pharmaceutical tariffs would have far-reaching implications beyond just the direct financial costs:
- Consumer Burden: While regulations on drug pricing and contracts may limit the ability of pharmaceutical companies to directly pass on tariff costs to consumers in the form of higher retail prices, the burden would still be borne by American households. If companies absorb the costs, it would likely lead to lower profits, which in turn could mean reduced wages for workers, lower returns for shareholders, and crucially, less reinvestment in R&D for new drug development. This represents a hidden cost, impacting economic growth and future healthcare advancements.
- Supply Chain Resilience vs. Disruption: The stated aim of tariffs is often to encourage reshoring of manufacturing and build more resilient domestic supply chains. However, restructuring global pharmaceutical supply chains is an incredibly complex, costly, and time-consuming endeavor. In the short to medium term, tariffs could paradoxically disrupt existing, albeit globally distributed, reliable supply chains, potentially leading to shortages of critical medicines as companies struggle to adapt or relocate production. Even if firms decide to move production to the U.S., it would not be a quick or cost-free process, and consumers could experience temporary disruptions.
- Innovation and Research & Development: The pharmaceutical industry is characterized by extremely high R&D costs and long development timelines for new drugs. Reduced profits due to tariffs could directly impact the funds available for R&D, potentially slowing the pace of innovation. This could mean fewer new treatments for diseases, delaying access to cutting-edge therapies for patients, and ultimately undermining the U.S.’s leadership in medical science.
- International Trade Relations: Unilateral imposition of tariffs often invites retaliatory measures from affected trading partners. The EU, a major supplier of pharmaceuticals to the U.S., could respond with its own tariffs on American goods, escalating trade tensions and potentially harming other U.S. export industries. Such actions could destabilize global trade relationships and create an environment of uncertainty for multinational corporations.
- Inflationary Pressures: Tariffs are fundamentally a tax on imports, and this cost often gets passed on throughout the supply chain, contributing to broader inflationary pressures within the economy. For a sector as critical as pharmaceuticals, these cost increases could ripple through the entire healthcare system, impacting insurance premiums, government healthcare spending programs, and ultimately the overall cost of living for Americans.
Methodological Considerations
The estimations presented rely on a robust methodology, incorporating economic models and industry-specific data. An elasticity of -2, based on research from Boehm et al. and the USITC, was applied to estimate the direct revenue effect of tariffs, alongside an assumed noncompliance rate of 8 percent. To determine the net revenue effect, an income and payroll tax offset of 0.232 for 2026 was incorporated into a microsimulation model.
The broad tariff base was established by analyzing all 815 HTS codes for pharmaceutical products exempted under Annex 3. An important adjustment was made for chemical imports, assuming that 18 percent of their import value is specifically for pharmaceutical preparations, recognizing that broad chemical categories span multiple industries. Furthermore, the split between branded and generic drug imports was estimated by aligning it with their respective drug spending shares, leading to the assumption that 90 percent of drug imports by value are branded drugs.
Conclusion
The threat of pharmaceutical tariffs, though not yet realized as of early 2026, represents a significant potential shift in U.S. trade and healthcare policy. Driven by national security concerns and a desire to bolster domestic manufacturing, these proposed tariffs could add between $19.7 billion and $23 billion in new costs to the U.S. economy. While proponents argue for enhanced supply chain resilience, the economic analysis suggests that such measures would act as a hidden tax on Americans, whether through directly higher drug prices, reduced wages, diminished investment in R&D, or potential short-term drug shortages.
Even if regulations prevent firms from passing costs directly to consumers, the burden would manifest in other ways, impacting corporate profitability, worker compensation, and the capacity for innovation that drives medical advancements. The complex interplay of global supply chains, drug pricing dynamics, and international trade relations means that any imposition of tariffs on pharmaceuticals would have multifaceted and potentially far-reaching consequences, demanding careful consideration of both the intended and unintended impacts on American health and economic well-being. The ongoing Section 232 investigation underscores the persistent nature of this debate and the critical decisions that lie ahead for the future of U.S. pharmaceutical policy.
